The industrial research centre (IRC) for functional RNA delivery, FoRmulaEx, is an eight-year agreement between Chalmers University of Technology, University of Gothenburg, Karolinska Institutet, company partners and the Swedish Foundation for Strategic Research (SSF). The purpose is to carry out research and innovation to contribute fundamental knowledge required to succeed in the development of next generation nucleotide-based drug delivery. All partners, with AstraZeneca acting as the leading company partner, jointly invest resources in the Formulaex centre in order to carry out research projects along a common plan identified based on critical bottlenecks in the present understanding of drug formulation and the delivery process. The Formulaex centre is administered and hosted by Chalmers, Department of Physics. To date, four companies (AstraZeneca, Camurus, Vironova and Nanolyze) collaborate with the academic partners through FoRmulaEx centre in six interconnected research projects. The vision of the Formulaex centre is to contribute fundamental knowledge required for the design of safe and efficient nanoscale drug-delivery vehicles for next generation nucleotide drugs, which function by reprogramming the genetic code of cells, rather than acting directly at the functional protein machinery as today’s drugs. The multidisciplinary approach taken involve expertise in physics, chemistry, biology, medicine and pharma and the knowledge and innovation generated aim and contributing significantly to Swedish competitiveness in this segment of research and development. The mission of the Formulaex centre is to bring fundamental scientific advances aimed for future drug-delivery formulations and analytical tools faster to industrial exploitation.